Primary Central Nervous System LymphomaPhase 2FIORELLANCT03495960
Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System
A Phase 2 study testing Rituximab, Methotrexate and Procarbazine in people with Primary Central Nervous System Lymphoma, run by International Extranodal Lymphoma Study Group (IELSG) at 34 sites in 4 countries.
Trial summary
Primary central nervous system lymphomas are rare aggressive malignancies, usually treated in two steps: an induction phase (where a combination of chemotherapy is given) followed by a consolidation phase (where patients usually receive one of the following: whole-brain irradiation, chemotherapy supported by… Read more about this study
- Who is it for?
- Ages 70 years and older
- Conditions the study is for
- Primary Central Nervous System Lymphoma
- What is being tested?
- Rituximab, Methotrexate and Procarbazine
- Type of treatment
- Pill or oral medicine, Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 72 participants
- Where
- 34 sitesin 4 countries
- Study dates
- 15 Jun 2019to 12 Dec 2024
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 70 years and older
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- Histologically or cytologically assessed diagnosis of CD20+ diffuse large B-cell lymphoma.
- Diagnostic sample obtained by stereotactic or surgical biopsy, CSF cytology examination or vitrectomy.
- Lymphoma exclusively localized in the central nervous system (brain parenchyma and/or meningeal/CSF dissemination and/or eyes and/or cranial nerves).
- Previously untreated patients (previous or ongoing steroid therapy admitted).
- Age ≥70 years
- Patients not eligible for high-dose chemotherapy supported by autologous stem cell transplant
Show all 14Show fewer
- ECOG PS ≤3.
- Adequate bone marrow, cardiac, renal, and hepatic function
- No previous or concurrent malignancies with the exception of surgically cured carcinoma in-situ of the cervix, carcinoma of the skin or other cancers without evidence of disease at least for 3 years (patients with a previous lymphoma at any time are NOT eligible).
- Absence of any familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
- No concurrent treatment with other experimental drugs.
- Patients receiving oral lenalidomide or procarbazine must agree to avoid sharing the study medication with another person and to return all unused study drug to the investigator.
- Male patients must agree to always use a latex or synthetic condom during any sexual contact with females of reproductive potential while taking lenalidomide, during dose interruptions and for up to 7 days after treatment discontinuation, even if they have undergone a successful vasectomy.
- Informed consent from the patient, or legal representative, obtained before registration.
Who cannot join
- Lymphoma entity other than diffuse large B-cell lymphoma.
- Extra-CNS disease.
- Lymphoma exclusively localized in the eyes
- Lymphoma infiltration of the cranial nerves as exclusive site of disease
- Previous antineoplastic treatment for the PCNSL.
- Patients eligible for ASCT.
Show all 11Show fewer
- HBsAg- and HCV-positive patients; HBsAg- and HCV-positive patients. HBcAb+ is not exclusion criteria in the absence of detectable levels HBVDNA.
- HIV disease or immunodeficiency.
- Severe concomitant illnesses/medical conditions (e.g. impaired respiratory and/or cardiac function, uncontrolled diabetes mellitus despite optimal medical management).
- Active infectious disease.
- Hypersensitivity to any active principle and/or any excipient according to the contraindications reported in the Summary of Product Characteristics (SmPCs) of the anticancer drugs used in the study
Trial locations and contacts
34 sites in 4 countries.
34 sites in 4 countries
Italy25 sites
Ospedale C.e G. Mazzoni
Ascoli Piceno
Centro di Riferimento Oncologico
Aviano, (PN), 33081
Bari IRCCS Istituto Tumori
Bari
ASST Spedali Civili di Brescia
Brescia
Ospedale Antonio Perrino
Brindisi
Azienda Ospedaliera Universitaria (AOU) Careggi
Florence
Meldola, IRST - ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI
Meldola
Milano, IRCCS Ospedale San Raffaele
Milan, 20132
Milano - Îstituto Besta
Milan
Milano Niguarda
Milan
Modena, Policlinico Universitario
Modena
ASST Monza - Ospedale S. Gerardo
Monza
Pescara, Presidio Ospedaliero UOS dipartimentale centro di diagnosi e terapia Linfomi
Pescara
Piacenza
Piacenza
Ravenna - Ospedale di Ravenna - IRST
Ravenna
Reggio Emilia - Arcispedale Santa Maria Nuova - IRCCS
Reggio Emilia
AUSL della Romagna - Presidio Ospedaliero Rimini - Ospedale "Infermi"
Rimini
Policlinico Umberto I - Università La Sapienza
Roma
Roma - Unicampus-Bio
Roma
S. Giovanni Rotondo - Casa Sollievo della sofferenza
San Giovanni Rotondo
Siena - Azienda Ospedaliera Universitaria Senese
Siena
Terni - Ospedale di Terni
Terni
Torino neurooncologia - AOU CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO
Torino
Tricase - Ospedale "Card. G. Panico"
Tricase
Udine, Azienda Ospedaliera Universitaria
Udine
Switzerland5 sites
Basel - Universitätsspital
Basel
IOSI - Oncology Institute of Southern Switzerland
Bellinzona, 6500
Bern - Inselspital
Bern
St. Gallen - Kantonsspital
Sankt Gallen
Universitätsspital Zürich
Zurich, CH-8091
Denmark2 sites
Aarhus University Hospital
Aarhus
Odense University Hospital
Odense
Finland2 sites
Oulu University Hospital
Oulu
Tampere University Hospital
Tampere
About this study
Official title: Randomized Phase II Trial on Fitness- and Comorbidity- Tailored Treatment in Elderly Patients With Newly Diagnosed Primary CNS Lymphoma (FIORELLA Trial)
Primary central nervous system lymphomas are rare aggressive malignancies, usually treated in two steps: an induction phase (where a combination of chemotherapy is given) followed by a consolidation phase (where patients usually receive one of the following: whole-brain irradiation, chemotherapy supported by autologous stem-cell transplantation, other type of chemotherapy, or are just observed).
The feasibility of this overall strategy, for several reasons, is limited in elderly patients .
Read more
This study involves patients aged ≥70 years. The more fit patients will receive the standard chemotherapy combination (high-dose methotrexate, procarbazine and rituximab) as induction. Responding patients will receive either procarbazine or lenalidomide as maintenance therapy; the aim is to evaluate the efficacy of these two drugs.
The more fragile patients will receive a less aggressive therapy consisting of concomitant whole-brain radiotherapy, temozolomide and rituximab as induction therapy, followed by temozolomide as maintenance treatment; the aim is to evaluate the efficacy of this combination of treatment.
Read the detailed description
Primary central nervous system lymphomas (PCNSL) are rare aggressive malignancies, mostly of B-cell origin, representing 4% of intracranial neoplasms and 4-6% of extranodal non-Hodgkin's lymphomas (NHL). Despite improvements in treatment, PCNSL is associated with an aggressive course and unsatisfactory outcome. The median age at diagnosis is 61 years and age over 60 years has been reported to be an independent factor for a poorer outcome.
The modern treatment of PCNSL includes two phases: induction and consolidation. The induction phase usually consists of a polychemotherapy combination, including high-dose methotrexate as a critical drug, while there are at least four different strategies that can be used as consolidation: whole-brain irradiation, myeloblative chemotherapy supported by autologous stem-cell transplantation, non-myeloblative chemotherapy, observation (only in patients who achieve complete remission after induction).
The feasibility of this overall strategy is limited, for several reasons, in elderly patients with newly diagnosed PCNSL. High-doses of antimetabolite-based chemotherapy, the standard induction for patients younger than 70 years, is often not feasible in elderly patients. Among maintenance strategies, simple observation results in unacceptably high relapse rate and associated mortality while whole-brain irradiation and aggressive chemotherapies are associated with unacceptable toxicity and poor outcome. Thus, new strategies aimed at obtaining durable responses with an acceptable tolerability and reduced risk of neurocognitive decline are needed and these strategies should be tailored not only based on the patients' age but also on their specific co-morbidities and general health conditions.
For the present trial, all patients aged ≥70 years taken into care at the participating sites will be invited to participate and after informed consent signature their baseline data will be collected in the trial database, including data of patients resulting in screening failure. This will allow to verify any potential screening bias by comparing the characteristics of included and excluded patients. Patients fulfilling the eligibility criteria are then screened for their suitability to receive a more or less aggressive anticancer treatment and assigned to two different treatment strategies accordingly.
Part A:
The more fit patients are assigned to the trial Part A and will receive the standard combination of high-dose methotrexate, procarbazine and rituximab as induction. Responding patients will subsequently be randomized to receive either procarbazine or lenalidomide as maintenance therapy.
Procarbazine is a lipophilic oral alkylating agent, easily crossing the blood brain barrier (up to 100% of plasma levels). There is no known cumulative toxicity for procarbazine and it is therefore currently in use as a viable maintenance treatment option aimed at eliminating residual lymphoma cells in the CNS and reduce the risk of relapse. Lenalidomide is an oral immunomodulatory agent, active against diffuse large B cell lymphoma, the most common category in PCNSL, which can be taken for years, showing an excellent safety profile. On this background, the Part A of the present trial consists of a randomized phase II trial conducted in elderly patients with newly diagnosed PCNSL responsive to high-dose methotrexate-based chemotherapy, comparing two different maintenance strategies: the oral chemotherapeutic drug procarbazine and the oral immunomodulatory agent lenalidomide.
Part B:
The more fragile patients are assigned to the trial Part B and will receive a less aggressive therapy consisting of concomitant whole-brain radiotherapy, temozolomide and rituximab as induction therapy, followed by temozolomide single-agent as maintenance treatment.
Whole-brain radiotherapy is the main therapeutic choice for patients with contraindications to chemotherapy and in particular for elderly patients. Brain irradiation is usually associated with transient disruption of the blood-tumor barrier, occurring from 1 week after the initiation of radiotherapy to 1 month after its completion, during which pharmaceutical agents have maximum access to tumor tissue. Concomitant delivery of active cytostatics, therefore, could result in increased tumor uptake. Concomitant delivery of radiotherapy and temozolomide is currently used as standard approach for the treatment of high-grade gliomas, with acceptable toxicity despite the use of a larger irradiation dose. Based on the above, in the Part B of the present trial, temozolomide and rituximab, two agents active against PCNSL, are delivered concomitantly to whole-brain radiotherapy to obtain a synergistic effect of radiation damage, antineoplastic effect of rituximab and cytostatic and radiomimetic effects of temozolomide. Finally, temozolomide maintenance has shown to be beneficial regarding sustained remission after initial response to induction therapy and its suitability to improve disease control in responding patients not fit for more aggressive therapies will therefore be tested in the Part B of this trial.
- Conditions
- Primary Central Nervous System Lymphoma
- Being tested
- Rituximab, Methotrexate, Procarbazine, Lenalidomide, Radiotherapy
- Keywords
- non-Hodgkin's lymphoma, elderly, PCNSL
- Medical subject headings
- Lymphoma, Non-Hodgkin
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RituximabDrug
PART A - INDUCTION PHASE During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Rituximab is given 375 mg/m2 as standard infusion at days -6, 1, 15 \& 29. Rituximab on day -6 will be delivered only during the first course; it will be delivered between day -6 and day 0 according to clinical requirements and patient's conditions. Some patients would need for a fast chemotherapy starting.
PART B - INDUCTION PHASE Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Rituximab is given 375 mg/m2 in 4 weekly doses, starting on day 2 of radiotherapy.
MethotrexateDrug
During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Methotrexate is given 3 g/m2 as infusion (0.5 g/m2 in 15 min. + 2.5 g/m2 in 3-hr infusion) on days 2, 16 \& 30
ProcarbazineDrug
PART A - INDUCTION PHASE During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Procarbazine is given oral 60 mg/m2/d from days 2 to 11
PART A - MANTEINANCE PHASE (control arm) Patients responsive or with stable disease after two courses of PRIMAIN regimen (the induction treatment) will be randomly allocated to receive two different maintenance therapies. Maintenance will start on day 60 of the 2nd PRIMAIN course.
Procarbazine represents the control arm and is given oral 100 mg/d from day 1 to 5 for 6 courses, every 4 weeks.
LenalidomideDrug
Patients responsive or with stable disease after two courses of PRIMAIN regimen (the induction treatment) will be randomly allocated to receive two different maintenance therapies. Maintenance will start on day 60 of the 2nd PRIMAIN course.
Lenalidomide represents the experimental arm and is given oral 25 mg/d from day 1 to 21 for 24 courses; every 4 weeks.
RadiotherapyRadiation
Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Whole-brain will be irradiated by two opposite lateral fields including the first two cervical vertebras and the posterior two thirds of the eyes. Photons of 4 - 10 MeV, 180 - 200 cGy per day, 5 weekly fractions will be employed
TemozolomideDrug
PART B - INDUCTION PHASE Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Temoyolomide is given 75 mg/m2/d, every day for the whole duration of radiotherapy.
PART B - MAINTENANCE PHASE Temozolomide is also given as maintenance in Part B. The treatment consists of 12 courses where temozolomide is administered on days 1-5, every 4 weeks at a dose of 150 mg/m2/d at the first course, and of 200 mg/m2/d at the subsequent courses,
| Study group | Role | What they receive |
|---|---|---|
| Lenalidomide (experimental arm of part A) | Experimental | Patients in part A will receive 2 courses of induction chemo-immunotherapy:
Rituximab 375 mg/m2 i.v. on days -6, 1, 15, 29; Methotrexate 3 g/m2 0.5 g/m2 in 15 min. +2.5 g/m2 in 3-hr inf. on days 2,16,30; Procarbazine 60 mg/m2/d oral on days 2 to 11.
The duration of each treatment course is 43 days. Patients will then be randomized to receive lenalidomide or procarbazine as maintenance therapy.
Lenalidomide is given 25 mg/d per os, days 1 to 21 every 4 weeks for 24 courses Receives: Drug: Rituximab; Drug: Methotrexate; Drug: Procarbazine; Drug: Lenalidomide |
| Procarbazine (comparator arm of part A) | Active comparator | Patients in part A will receive 2 courses of induction chemo-immunotherapy:
Rituximab 375 mg/m2 i.v. on days -6, 1, 15, 29; Methotrexate 3 g/m2 0.5 g/m2 in 15 min. +2.5 g/m2 in 3-hr inf. on days 2,16,30; Procarbazine 60 mg/m2/d oral on days 2 to 11.
The duration of each treatment course is 43 days. Patients will then be randomized to receive lenalidomide or procarbazine as maintenance therapy.
Procarbazine is given 100 mg/d per os, days 1 to 5 every 4 weeks for 6 courses Receives: Drug: Rituximab; Drug: Methotrexate; Drug: Procarbazine |
| Radiotherapy, temozolomide and rituximab (single arm part B) | Other | Patients ineligible for high-dose-methotrexate will be treated in the single-arm phase II part B of the trial and will receive
* whole-brain radiotherapy (2340 cGy in 5 weekly fractions)
* temozolomide 75 mg/m2/d during radiotherapy
* 4 weekly doses of rituximab 375 mg/m2, starting on day 2 of the whole-brain radiotherapy.
Patients will then receive maintenance therapy with 12 courses of temozolomide administered on days 1-5, every 4 weeks at a dose of 150 mg/m2/d at the first course, and of 200 mg/m2/d at the subsequent courses. Receives: Drug: Rituximab; Radiation: Radiotherapy; Drug: Temozolomide |
What is being measured
The primary outcome is the main question the study is designed to answer.
Two years Progression Free Survival (PFS) - part A
The primary objective is to evaluate whether lenalidomide administered as maintenance treatment after achievement of disease stabilization or better response by standard induction therapy results in a higher 2-year PFS rate as compared to procarbazine maintenance.
The corresponding primary endpoint is the difference in 2-years PFS between the two treatment arms.
Measured: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years.
Two years Progression Free Survival (PFS) - part B
Measured: From date of maintenance start until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years
Secondary outcomes (6)
Duration of response (part A)
Difference between the two arms in time from first assessment of response (PR or CR) to relapse/progression
Measured: From date of first assessment of response (PR or CR) until the date of first documented progression, assessed up to 2 years from randomization.
Response Rates (part B)
Proportion of patients showing CR, PR, SD, PD as best response to treatment
Measured: From the start of the treatment until disease progression, assessed up to 2 years from start of maintenance.
Overall survival (OS)
Measured: From date of induction treatment start until the date of death from any cause or the date of the last visit in patients still alive at study end, assessed up to 2 years from start of maintenance.
Relapse rates and patterns
Analysis of the following relapse rates and patterns: primary site vs. secondary CNS sites vs. extra-CNS sites; CNS sites: brain, meninges, cranial nerves, and/or eyes
Measured: From the start of the treatment until disease progression, assessed up to 2 years from start of maintenance.
Incidence of Treatment-Emergent Adverse Events
Analysis of adverse events and adverse reactions incidence and severity
Measured: From the 2 weeks preceding treatment start through study completion, an average of 2.5 years
Early and late neurotoxicity
Analysis of incidence and severity of early and late neurotoxicity assessed by specific neuropsychological and quality of life tests up to 2 years from maintenance treatment start
Measured: From maintenance up to 2 years.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Apr 2018
- Study start15 Jun 2019
- Primary completion12 Dec 2024
- Study completion12 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Primary Central Nervous System LymphomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Multicenter open label phase II trial. The patients will be stratified according to their suitability to tolerate an induction chemo-immunotherapy regimen containing high-dose methotrexate. Patients eligible for high-dose methotrexate-based induction chemotherapy will enter the run-in phase of Part A of the study and after the induction phase will be randomly assigned to procarbazine or lenalidomide maintenance monotherapy. Forty assessable patients per treatment arm are required. Patients ineligible for high-dose methotrexate-based induction chemotherapy will be treated în Part B with concomitant whole-brain radiotherapy, temozolomide and rituximab and will receive temozolomide as maintenance.According to the Simon's two-stage minimax design, 46 patients will be treated in the first stage. If ≤ 16 patients will be progression-free at 2 years from maintenance treatment start, the study will be stopped. Otherwise, 19 additional patients will be treated for a total of 65
- Masking
- None (open label)
- Enrolment
- 72 participants (actual)
Sponsor and investigators
- Lead sponsor
- International Extranodal Lymphoma Study Group (IELSG)
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Andrès JM Ferreri, MD, Study chair, IRCCS San Raffaele Scientific Institute, Milan, Italy
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03495960
- Sponsor's protocol ID
- IELSG45
- Acronym
- FIORELLA
- Status last verified
- Jan 2025
- First submitted
- 23 Mar 2018
- Last updated
- 30 Jan 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized Phase II Trial on Fitness- and Comorbidity- Tailored Treatment in Elderly Patients With Newly Diagnosed Primary CNS Lymphoma (FIORELLA Trial)
- ClinicalTrials.gov ID
- NCT03495960
- Acronym / sponsor ID
- FIORELLA / IELSG45
- Conditions
- Primary Central Nervous System Lymphoma
- Keywords
- non-Hodgkin's lymphoma, elderly, PCNSL
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 72 participants (actual)
- Lead sponsor
- International Extranodal Lymphoma Study Group (IELSG)University, hospital or other
- Study start
- 15 Jun 2019 (actual)
- Primary completion
- 12 Dec 2024 (actual)
- Study completion
- 12 Dec 2024 (actual)
- First posted
- 12 Apr 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Primary central nervous system lymphomas are rare aggressive malignancies, usually treated in two steps: an induction phase (where a combination of chemotherapy is given) followed by a consolidation phase (where patients usually receive one of the following: whole-brain irradiation, chemotherapy supported by autologous stem-cell transplantation, other type of chemotherapy, or are just observed).
The feasibility of this overall strategy, for several reasons, is limited in elderly patients .
This study involves patients aged ≥70 years. The more fit patients will receive the standard chemotherapy combination (high-dose methotrexate, procarbazine and rituximab) as induction. Responding patients will receive either procarbazine or lenalidomide as maintenance therapy; the aim is to evaluate the efficacy of these two drugs.
The more fragile patients will receive a less aggressive therapy consisting of concomitant whole-brain radiotherapy, temozolomide and rituximab as induction therapy, followed by temozolomide as maintenance treatment; the aim is to evaluate the efficacy of this combination of treatment.
Detailed description
Primary central nervous system lymphomas (PCNSL) are rare aggressive malignancies, mostly of B-cell origin, representing 4% of intracranial neoplasms and 4-6% of extranodal non-Hodgkin's lymphomas (NHL). Despite improvements in treatment, PCNSL is associated with an aggressive course and unsatisfactory outcome. The median age at diagnosis is 61 years and age over 60 years has been reported to be an independent factor for a poorer outcome.
The modern treatment of PCNSL includes two phases: induction and consolidation. The induction phase usually consists of a polychemotherapy combination, including high-dose methotrexate as a critical drug, while there are at least four different strategies that can be used as consolidation: whole-brain irradiation, myeloblative chemotherapy supported by autologous stem-cell transplantation, non-myeloblative chemotherapy, observation (only in patients who achieve complete remission after induction).
The feasibility of this overall strategy is limited, for several reasons, in elderly patients with newly diagnosed PCNSL. High-doses of antimetabolite-based chemotherapy, the standard induction for patients younger than 70 years, is often not feasible in elderly patients. Among maintenance strategies, simple observation results in unacceptably high relapse rate and associated mortality while whole-brain irradiation and aggressive chemotherapies are associated with unacceptable toxicity and poor outcome. Thus, new strategies aimed at obtaining durable responses with an acceptable tolerability and reduced risk of neurocognitive decline are needed and these strategies should be tailored not only based on the patients' age but also on their specific co-morbidities and general health conditions.
For the present trial, all patients aged ≥70 years taken into care at the participating sites will be invited to participate and after informed consent signature their baseline data will be collected in the trial database, including data of patients resulting in screening failure. This will allow to verify any potential screening bias by comparing the characteristics of included and excluded patients. Patients fulfilling the eligibility criteria are then screened for their suitability to receive a more or less aggressive anticancer treatment and assigned to two different treatment strategies accordingly.
Part A:
The more fit patients are assigned to the trial Part A and will receive the standard combination of high-dose methotrexate, procarbazine and rituximab as induction. Responding patients will subsequently be randomized to receive either procarbazine or lenalidomide as maintenance therapy.
Procarbazine is a lipophilic oral alkylating agent, easily crossing the blood brain barrier (up to 100% of plasma levels). There is no known cumulative toxicity for procarbazine and it is therefore currently in use as a viable maintenance treatment option aimed at eliminating residual lymphoma cells in the CNS and reduce the risk of relapse. Lenalidomide is an oral immunomodulatory agent, active against diffuse large B cell lymphoma, the most common category in PCNSL, which can be taken for years, showing an excellent safety profile. On this background, the Part A of the present trial consists of a randomized phase II trial conducted in elderly patients with newly diagnosed PCNSL responsive to high-dose methotrexate-based chemotherapy, comparing two different maintenance strategies: the oral chemotherapeutic drug procarbazine and the oral immunomodulatory agent lenalidomide.
Part B:
The more fragile patients are assigned to the trial Part B and will receive a less aggressive therapy consisting of concomitant whole-brain radiotherapy, temozolomide and rituximab as induction therapy, followed by temozolomide single-agent as maintenance treatment.
Whole-brain radiotherapy is the main therapeutic choice for patients with contraindications to chemotherapy and in particular for elderly patients. Brain irradiation is usually associated with transient disruption of the blood-tumor barrier, occurring from 1 week after the initiation of radiotherapy to 1 month after its completion, during which pharmaceutical agents have maximum access to tumor tissue. Concomitant delivery of active cytostatics, therefore, could result in increased tumor uptake. Concomitant delivery of radiotherapy and temozolomide is currently used as standard approach for the treatment of high-grade gliomas, with acceptable toxicity despite the use of a larger irradiation dose. Based on the above, in the Part B of the present trial, temozolomide and rituximab, two agents active against PCNSL, are delivered concomitantly to whole-brain radiotherapy to obtain a synergistic effect of radiation damage, antineoplastic effect of rituximab and cytostatic and radiomimetic effects of temozolomide. Finally, temozolomide maintenance has shown to be beneficial regarding sustained remission after initial response to induction therapy and its suitability to improve disease control in responding patients not fit for more aggressive therapies will therefore be tested in the Part B of this trial.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
- Model description
- Multicenter open label phase II trial. The patients will be stratified according to their suitability to tolerate an induction chemo-immunotherapy regimen containing high-dose methotrexate. Patients eligible for high-dose methotrexate-based induction chemotherapy will enter the run-in phase of Part A of the study and after the induction phase will be randomly assigned to procarbazine or lenalidomide maintenance monotherapy. Forty assessable patients per treatment arm are required. Patients ineligible for high-dose methotrexate-based induction chemotherapy will be treated în Part B with concomitant whole-brain radiotherapy, temozolomide and rituximab and will receive temozolomide as maintenance.According to the Simon's two-stage minimax design, 46 patients will be treated in the first stage. If ≤ 16 patients will be progression-free at 2 years from maintenance treatment start, the study will be stopped. Otherwise, 19 additional patients will be treated for a total of 65
| Arm | Type | Receives |
|---|---|---|
| Lenalidomide (experimental arm of part A) | Experimental | Drug: Rituximab, Drug: Methotrexate, Drug: Procarbazine, Drug: LenalidomidePatients in part A will receive 2 courses of induction chemo-immunotherapy: Rituximab 375 mg/m2 i.v. on days -6, 1, 15, 29; Methotrexate 3 g/m2 0.5 g/m2 in 15 min. +2.5 g/m2 in 3-hr inf. on days 2,16,30; Procarbazine 60 mg/m2/d oral on days 2 to 11. The duration of each treatment course is 43 days. Patients will then be randomized to receive lenalidomide or procarbazine as maintenance therapy. Lenalidomide is given 25 mg/d per os, days 1 to 21 every 4 weeks for 24 courses |
| Procarbazine (comparator arm of part A) | Active comparator | Drug: Rituximab, Drug: Methotrexate, Drug: ProcarbazinePatients in part A will receive 2 courses of induction chemo-immunotherapy: Rituximab 375 mg/m2 i.v. on days -6, 1, 15, 29; Methotrexate 3 g/m2 0.5 g/m2 in 15 min. +2.5 g/m2 in 3-hr inf. on days 2,16,30; Procarbazine 60 mg/m2/d oral on days 2 to 11. The duration of each treatment course is 43 days. Patients will then be randomized to receive lenalidomide or procarbazine as maintenance therapy. Procarbazine is given 100 mg/d per os, days 1 to 5 every 4 weeks for 6 courses |
| Radiotherapy, temozolomide and rituximab (single arm part B) | Other | Drug: Rituximab, Radiation: Radiotherapy, Drug: TemozolomidePatients ineligible for high-dose-methotrexate will be treated in the single-arm phase II part B of the trial and will receive * whole-brain radiotherapy (2340 cGy in 5 weekly fractions) * temozolomide 75 mg/m2/d during radiotherapy * 4 weekly doses of rituximab 375 mg/m2, starting on day 2 of the whole-brain radiotherapy. Patients will then receive maintenance therapy with 12 courses of temozolomide administered on days 1-5, every 4 weeks at a dose of 150 mg/m2/d at the first course, and of 200 mg/m2/d at the subsequent courses. |
Who may qualify
- Ages
- 70 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (14 listed)
- Histologically or cytologically assessed diagnosis of CD20+ diffuse large B-cell lymphoma.
- Diagnostic sample obtained by stereotactic or surgical biopsy, CSF cytology examination or vitrectomy.
- Lymphoma exclusively localized in the central nervous system (brain parenchyma and/or meningeal/CSF dissemination and/or eyes and/or cranial nerves).
- Previously untreated patients (previous or ongoing steroid therapy admitted).
- Age ≥70 years
Key exclusion criteria (11 listed)
- Lymphoma entity other than diffuse large B-cell lymphoma.
- Extra-CNS disease.
- Lymphoma exclusively localized in the eyes
- Lymphoma infiltration of the cranial nerves as exclusive site of disease
- Previous antineoplastic treatment for the PCNSL.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RituximabPART A - INDUCTION PHASE During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Rituximab is given 375 mg/m2 as standard infusion at days -6, 1, 15 \& 29. Rituximab on day -6 will be delivered only during the first course; it will be delivered between day -6 and day 0 according to clinical requirements and patient's conditions. Some patients would need for a fast chemotherapy starting. PART B - INDUCTION PHASE Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Rituximab is given 375 mg/m2 in 4 weekly doses, starting on day 2 of radiotherapy. | Drug | Lenalidomide (experimental arm of part A), Procarbazine (comparator arm of part A), Radiotherapy, temozolomide and rituximab (single arm part B) |
| MethotrexateDuring the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Methotrexate is given 3 g/m2 as infusion (0.5 g/m2 in 15 min. + 2.5 g/m2 in 3-hr infusion) on days 2, 16 \& 30 | Drug | Lenalidomide (experimental arm of part A), Procarbazine (comparator arm of part A) |
| ProcarbazinePART A - INDUCTION PHASE During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Procarbazine is given oral 60 mg/m2/d from days 2 to 11 PART A - MANTEINANCE PHASE (control arm) Patients responsive or with stable disease after two courses of PRIMAIN regimen (the induction treatment) will be randomly allocated to receive two different maintenance therapies. Maintenance will start on day 60 of the 2nd PRIMAIN course. Procarbazine represents the control arm and is given oral 100 mg/d from day 1 to 5 for 6 courses, every 4 weeks. | Drug | Lenalidomide (experimental arm of part A), Procarbazine (comparator arm of part A) |
| LenalidomidePatients responsive or with stable disease after two courses of PRIMAIN regimen (the induction treatment) will be randomly allocated to receive two different maintenance therapies. Maintenance will start on day 60 of the 2nd PRIMAIN course. Lenalidomide represents the experimental arm and is given oral 25 mg/d from day 1 to 21 for 24 courses; every 4 weeks. | Drug | Lenalidomide (experimental arm of part A) |
| RadiotherapyPatients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Whole-brain will be irradiated by two opposite lateral fields including the first two cervical vertebras and the posterior two thirds of the eyes. Photons of 4 - 10 MeV, 180 - 200 cGy per day, 5 weekly fractions will be employed | Radiation | Radiotherapy, temozolomide and rituximab (single arm part B) |
| TemozolomidePART B - INDUCTION PHASE Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Temoyolomide is given 75 mg/m2/d, every day for the whole duration of radiotherapy. PART B - MAINTENANCE PHASE Temozolomide is also given as maintenance in Part B. The treatment consists of 12 courses where temozolomide is administered on days 1-5, every 4 weeks at a dose of 150 mg/m2/d at the first course, and of 200 mg/m2/d at the subsequent courses, | Drug | Radiotherapy, temozolomide and rituximab (single arm part B) |
Primary outcome
Two years Progression Free Survival (PFS) - part A
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years.
The primary objective is to evaluate whether lenalidomide administered as maintenance treatment after achievement of disease stabilization or better response by standard induction therapy results in a higher 2-year PFS rate as compared to procarbazine maintenance. The corresponding primary endpoint is the difference in 2-years PFS between the two treatment arms.
Two years Progression Free Survival (PFS) - part B
Time frame: From date of maintenance start until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years
6 secondary outcomes
Duration of response (part A)
Time frame: From date of first assessment of response (PR or CR) until the date of first documented progression, assessed up to 2 years from randomization.
Response Rates (part B)
Time frame: From the start of the treatment until disease progression, assessed up to 2 years from start of maintenance.
Overall survival (OS)
Time frame: From date of induction treatment start until the date of death from any cause or the date of the last visit in patients still alive at study end, assessed up to 2 years from start of maintenance.
Relapse rates and patterns
Time frame: From the start of the treatment until disease progression, assessed up to 2 years from start of maintenance.
Incidence of Treatment-Emergent Adverse Events
Time frame: From the 2 weeks preceding treatment start through study completion, an average of 2.5 years
Early and late neurotoxicity
Time frame: From maintenance up to 2 years.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jan 2025.
Related trials for Primary Central Nervous System Lymphoma
RecruitingPhase 2
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
Non-hodgkin Lymphoma
RecruitingPhase 1
Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma
Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
RecruitingPhase 2
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Lymphoma
RecruitingPhase 1
Phase Ib Clinical Study of Keynatinib
Lymphoma, B-Cell
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Andrès JM Ferreri, MD study chair
IRCCS San Raffaele Scientific Institute, Milan, Italy
34 sites in 4 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Rituximab, Methotrexate and Procarbazine in people with Primary Central Nervous System Lymphoma, run by International Extranodal Lymphoma Study Group (IELSG) at 34 sites in 4 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 34 sites in Italy, Switzerland, Denmark, Finland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Two years Progression Free Survival (PFS) - part A (time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jan 2025.